Table of Contents

Global Biosimilars Treatment Market Segment Research Report 2022

1. Research Scope

2. Market Overview

• 2.1 Product Introduction, Application, Picture
• 2.2 Global Biosimilars Treatment Market by Value
  • 2.2.1 Global Biosimilars Treatment Revenue by Type
  • 2.2.2 Global Biosimilars Treatment Market by Value (%)
• 2.3 Global Biosimilars Treatment Market by Production
  • 2.3.1 Global Biosimilars Treatment Production by Type
  • 2.3.2 Global Biosimilars Treatment Market by Production (%)

3. The Major Driver of Biosimilars Treatment Industry

• 3.1 Historical & Forecast Global Biosimilars Treatment Demand
• 3.2 Largest Application for Biosimilars Treatment (2018-2028)
• 3.3 The Major Downstream Company in China Market 2022

4. Global and Regional Biosimilars Treatment Market

• 4.1 Regional Market Size in Terms of Production & Demand (2022)
• 4.2 Regional Market Share in Terms of Revenue (2018-2022)
• 4.3 Concentration Ratio (CR5& CR10) of Biosimilars Treatment Market
• 4.4 Mergers & Acquisitions, Expansion Plans

5. US Biosimilars Treatment Production, Demand (2018-2028)

• 5.1 Current and Estimated Production Breakdown by Type
• 5.2 Current and Estimated Demand Breakdown by Type
• 5.3 Current and Estimated Demand Breakdown by Application
• 5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
• 5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe Biosimilars Treatment Production, Demand (2018-2028)

• 6.1 Current and Estimated Production Breakdown by Type
• 6.2 Current and Estimated Demand Breakdown by Type
• 6.3 Current and Estimated Demand Breakdown by Application
• 6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
• 6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China Biosimilars Treatment Production, Demand (2018-2028)

• 7.1 Current and Estimated Production Breakdown by Type
• 7.2 Current and Estimated Demand Breakdown by Type
• 7.3 Current and Estimated Demand Breakdown by Application
• 7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
• 7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan Biosimilars Treatment Production, Demand (2018-2028)

• 8.1 Current and Estimated Production Breakdown by Type
• 8.2 Current and Estimated Demand Breakdown by Type
• 8.3 Current and Estimated Demand Breakdown by Application
• 8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
• 8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India Biosimilars Treatment Production, Demand (2018-2028)

• 9.1 Current and Estimated Production Breakdown by Type
• 9.2 Current and Estimated Demand Breakdown by Type
• 9.3 Current and Estimated Demand Breakdown by Application
• 9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
• 9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea Biosimilars Treatment Production, Demand (2018-2028)

• 10.1 Current and Estimated Production Breakdown by Type
• 10.2 Current and Estimated Demand Breakdown by Type
• 10.3 Current and Estimated Demand Breakdown by Application
• 10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
• 10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia Biosimilars Treatment Production, Demand (2018-2028)

• 11.1 Current and Estimated Production Breakdown by Type
• 11.2 Current and Estimated Demand Breakdown by Type
• 11.3 Current and Estimated Demand Breakdown by Application
• 11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
• 11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global Biosimilars Treatment Average Price Trend

• 12.1 Market Price for Each Type of Biosimilars Treatment in US (2018-2022)
• 12.2 Market Price for Each Type of Biosimilars Treatment in Europe (2018-2022)
• 12.3 Market Price for Each Type of Biosimilars Treatment in China (2018-2022)
• 12.4 Market Price for Each Type of Biosimilars Treatment in Japan (2018-2022)
• 12.5 Market Price for Each Type of Biosimilars Treatment in India (2018-2022)
• 12.6 Market Price for Each Type of Biosimilars Treatment in Korea (2018-2022)
• 12.7 Market Price for Each Type of Biosimilars Treatment in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)

• 13.1 Biosimilars Treatment Industrial Chain Analysis
• 13.2 Downstream
• 13.3 Impact of COVID-19
• 13.4 Post-pandemic Era
• 13.5 Technology Trends of Biosimilars Treatment

14. Biosimilars Treatment Competitive Landscape

• 14.1 Bayer
  • 14.1.1 Bayer Company Profiles
  • 14.1.2 Bayer Product Introduction
  • 14.1.3 Bayer Biosimilars Treatment Sales, Revenue (2018-2022)
  • 14.1.4 Strategic initiatives
• 14.2 Eli Lily, Inc.
  • 14.2.1 Eli Lily, Inc. Company Profiles
  • 14.2.2 Eli Lily, Inc. Product Introduction
  • 14.2.3 Eli Lily, Inc. Biosimilars Treatment Sales, Revenue (2018-2022)
  • 14.2.4 Strategic initiatives
• 14.3 Pfizer, Inc.
  • 14.3.1 Pfizer, Inc. Company Profiles
  • 14.3.2 Pfizer, Inc. Product Introduction
  • 14.3.3 Pfizer, Inc. Biosimilars Treatment Sales, Revenue (2018-2022)
  • 14.3.4 Strategic initiatives
• 14.4 Sandoz International GmbH
  • 14.4.1 Sandoz International GmbH Company Profiles
  • 14.4.2 Sandoz International GmbH Product Introduction
  • 14.4.3 Sandoz International GmbH Biosimilars Treatment Sales, Revenue (2018-2022)
  • 14.4.4 Strategic initiatives
• 14.5 Teva Pharmaceutical Industries Limited
  • 14.5.1 Teva Pharmaceutical Industries Limited Company Profiles
  • 14.5.2 Teva Pharmaceutical Industries Limited Product Introduction
  • 14.5.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Sales, Revenue (2018-2022)
  • 14.5.4 Strategic initiatives
• 14.6 Amgen Inc.
  • 14.6.1 Amgen Inc. Company Profiles
  • 14.6.2 Amgen Inc. Product Introduction
  • 14.6.3 Amgen Inc. Biosimilars Treatment Sales, Revenue (2018-2022)
  • 14.6.4 Strategic initiatives
• 14.7 Biocon
  • 14.7.1 Biocon Company Profiles
  • 14.7.2 Biocon Product Introduction
  • 14.7.3 Biocon Biosimilars Treatment Sales, Revenue (2018-2022)
  • 14.7.4 Strategic initiatives
• 14.8 Dr. Reddy’s Laboratories
  • 14.8.1 Dr. Reddy’s Laboratories Company Profiles
  • 14.8.2 Dr. Reddy’s Laboratories Product Introduction
  • 14.8.3 Dr. Reddy’s Laboratories Biosimilars Treatment Sales, Revenue (2018-2022)
  • 14.8.4 Strategic initiatives
• 14.9 Roche Ltd.
  • 14.9.1 Roche Ltd. Company Profiles
  • 14.9.2 Roche Ltd. Product Introduction
  • 14.9.3 Roche Ltd. Biosimilars Treatment Sales, Revenue (2018-2022)
  • 14.9.4 Strategic initiatives
• 14.10 Celltrion, Inc.
  • 14.10.1 Celltrion, Inc. Company Profiles
  • 14.10.2 Celltrion, Inc. Product Introduction
  • 14.10.3 Celltrion, Inc. Biosimilars Treatment Sales, Revenue (2018-2022)
  • 14.10.4 Strategic initiatives
• 14.11 Samsung Bioepis

15. Conclusion

16. Methodology and Data Source

Summary

The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.

2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.

According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.

Beijing Yanjing Bizhi Information Consulting Co., Ltd. （XYZResearch）released the 《(Post-pandemic Era)-Global Biosimilars Treatment Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Biosimilars Treatment industry at home and abroad, estimate the overall market scale of the Biosimilars Treatment industry and the market share of major countries, Biosimilars Treatment industry, and study and judge the downstream market demand of Biosimilars Treatment through systematic research, Analyze the competition pattern of Biosimilars Treatment, so as to help solve the pain points of various stakeholders in Biosimilars Treatment industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.

Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Biosimilars Treatment Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Biosimilars Treatment Market?
Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy’s Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis
Major Type of Biosimilars Treatment Covered in XYZResearch report:
Recombinant Non – Glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides
Application Segments Covered in XYZResearch Market
Oncology
Chronic and Autoimmune Disease
Blood Disorders
Growth Hormone Disease
Infectious Disease

For any other requirements, please feel free to contact us and we will provide you customized report.